Crossmark

Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models

Crossref DOI link: https://doi.org/10.1136/jitc-2021-003368

Published Online: 2022-01-11

Published Print: 2022-01

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Koch, Marilin S https://orcid.org/0000-0002-8335-3543
Zdioruk, Mykola

Nowicki, Michal O

Griffith, Alec M https://orcid.org/0000-0002-4289-3017
Aguilar, Estuardo

Aguilar, Laura K

Guzik, Brian W

Barone, Francesca

Tak, Paul P

Tabatabai, Ghazaleh

Lederer, James A

Chiocca, E Antonio

Lawler, Sean
Funding

Funding for this research was provided by:

NCI (P01CA069246)

NCI (R50 CA243706-02)

Else-Kroener-Fresenius foundation (2015_Kolleg_14)
License Information

License valid from 2022-01-11